Clinical trials: Filariasis
Loiasis With Positive Blood Microfilaremia, Loiasis
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
- Trial name
- STOP-FiLAR-ALB (NCT06613997)
- Testing
- Albendazole 400mg
- Volunteers
- 100 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
HIV Infection, Lymphatic Filariasis
Interaction Between HIV and Lymphatic Filariasis
The impact of lymphatic filariasis (LF) on HIV is assessed by measuring HIV viral load before and after DEC treatment of filariasis in double-infected individuals.
- Trial name
- NCT00295698
- Testing
- Diethylcarbamazine
- Sponsor
- DBL -Institute for Health Research and Development
Leprosy, Buruli Ulcer
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Appropriate targeting of interventions for neglected tropical diseases (NTDs) that require innovative and intensified disease management (IDM) requires accurate data on the distribution of these diseases within endemic countries.
- Conditions
- Leprosy, Buruli Ulcer, Yaws, Lymphatic Filariases
- Trial name
- NCT03683745
- Where
- Liberia
- Volunteers
- 56,285 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Lymphatic Filariasis
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date and most of them are more than 15 years old.
- Trial name
- NCT02784743
- Testing
- ''albendazole'' and ''ivermectin''
- Volunteers
- 1,139 people, healthy volunteers welcome
- Sponsor
- Centre d'Appui à la lutte contre la Maladie
Lymphatic Filariasis, Helminth Infection
Twice Yearly Treatment for the Control of LF
The Global Program for the Elimination of Lymphatic Filariasis (GPELF) has been in operation sing the year 2000, with the aim of eliminating the disease by the year 2020, following 5-6 rounds of effective annual Mass Drug…
- Trial name
- NCT03036059
- Testing
- 400 μg/kg Ivermectin + 400 mg Albendazole
- Where
- Ghana
- Volunteers
- 1,462 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Filariasis
Relative Bioavailability Study of Emodepside IR-tablets and Solution
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov…
- Trial name
- NCT03383523
- Testing
- Emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
The DOLF Ocular Changes after Ivermectin study will investigate the kinetics of O. volvulus microfilaria (Mf) in the eye following treatment with ivermectin.
- Trial name
- NCT03517462
- Testing
- Ivermectin 3Mg Tab
- Where
- Ghana
- Volunteers
- 231 people
- Sponsor
- Washington University School of Medicine
Loiasis
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Background: Loa loa is a small worm that infects people in West and Central Africa. It is spread by the bite of a fly. Adult worms live under the skin and can cause swelling in the arms, legs, and face.
- Trial name
- NCT01593722
- Testing
- Diethylcarbamazine, Ivermectin
- Where
- Cameroon
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
This study is conducted in Kerala, India. It will determine whether a new treatment regimen of albendazole and diethylcarbamazine (DEC) for lymphatic filariasis can eliminate the disease more quickly than the standard regimen.
- Trial name
- NCT00511004
- Testing
- Albendazole, Diethylcarbamazine
- Where
- India
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
- Trial name
- NCT00127504
- Testing
- Rifampin, Azithromycin
- Where
- Guatemala
- Volunteers
- 80 people
- Sponsor
- Centers for Disease Control and Prevention
Onchocerciasis
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
The purpose of this study is to measure the amount of moxidectin in subjects' blood and to measure safety. This study will enroll 36 children aged 4 to 11 years (>=12 kg) with or without Onchocerca volvulus (O volvulus)…
- Trial name
- NCT01035619
- Testing
- moxidectin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Nodding Syndrome, Epilepsy
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Background: Childhood epilepsy disorders are particular frequent in the area around Mahenge, southern Tanzania and recent studies have described a novel type of epilepsy with repetitive head nodding episodes and often progressive…
- Conditions
- Nodding Syndrome, Epilepsy, Onchocerciasis, Cognitive Impairment
- Trial name
- NSEC (NCT03653975)
- Testing
- no intervention
- Where
- Tanzania
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Lymphedema, Lymphatic Filariasis
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
Current lymphedema management protocols are based on the use of simple measures of hygiene (regular washing with soap and water, skin and nail care), use of topical antibiotics or antifungal agents, exercise and footwear.
- Conditions
- Lymphedema, Lymphatic Filariasis, Filariasis
- Trial name
- LeDoxy-SL (NCT02929134)
- Testing
- Doxycycline
- Where
- Sri Lanka
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- The Task Force for Global Health
Lymphatic Filariasis, Onchocerciasis
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- DOLF-LIBERIA (NCT01905436)
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
- Where
- Liberia
- Volunteers
- 21,862 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Safety and Efficacy of IDA for Onchocerciasis
This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and…
- Trial name
- DOLF IDA/Oncho (NCT04188301)
- Testing
- IVM w/ ALB, Single dose of IDA, Three daily doses of IDA
- Where
- Ghana
- Volunteers
- 154 people
- Sponsor
- Washington University School of Medicine
Filariasis, Lymphatic, Onchocerciasis
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Lymphatic filariasis and onchocerciasis are a group of neglected tropical diseases caused by the transmission of worm larvae (microfilaria) by biting insects.
- Trial name
- AWOL (NCT05084560)
- Testing
- AWZ1066S
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Filarial Infection, HIV Infections
Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis
This study, sponsored by the National Institutes of Health and the Tuberculosis Research Centre and YRG-Care in Chennai, India, will examine how treatment of lymphatic filariasis in HIV-infected patients influences the amount of…
- Trial name
- NCT00344279
- Where
- 3 sites in India
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis, Loiasis
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for onchocerciasis compared to the gold standard which are the skin snips.
- Conditions
- Onchocerciasis, Loiasis, Diagnoses Disease, Neglected Diseases
- Trial name
- EOLoa (NCT04035174)
- Testing
- LTS-2 DEC patch, Skin snips
- Where
- Cameroon
- Volunteers
- healthy volunteers welcome
- Sponsor
- Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Onchocerciasis, Loiasis
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases.
- Conditions
- Onchocerciasis, Loiasis, Mansonelliasis, Healthy Volunteers
- Trial name
- Obi1 (NCT06350851)
- Testing
- Biological samples collection (blood drawing + feces)
- Where
- Cameroon
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Bioaster
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine